MY161853A - Pharmaceutical composition and method for treating hypertension - Google Patents
Pharmaceutical composition and method for treating hypertensionInfo
- Publication number
- MY161853A MY161853A MYPI2012004815A MYPI2012004815A MY161853A MY 161853 A MY161853 A MY 161853A MY PI2012004815 A MYPI2012004815 A MY PI2012004815A MY PI2012004815 A MYPI2012004815 A MY PI2012004815A MY 161853 A MY161853 A MY 161853A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceutical composition
- treating hypertension
- hypertension
- dextromethorphan
- amlodipine
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 abstract 2
- 229960001985 dextromethorphan Drugs 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33054010P | 2010-05-03 | 2010-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY161853A true MY161853A (en) | 2017-05-15 |
Family
ID=44903590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012004815A MY161853A (en) | 2010-05-03 | 2011-04-29 | Pharmaceutical composition and method for treating hypertension |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130053411A1 (https=) |
| EP (1) | EP2566478A4 (https=) |
| JP (1) | JP5847162B2 (https=) |
| KR (1) | KR20130061148A (https=) |
| CN (1) | CN102869360B (https=) |
| AU (1) | AU2011250485B2 (https=) |
| BR (1) | BR112012028153A2 (https=) |
| MY (1) | MY161853A (https=) |
| RU (1) | RU2571284C2 (https=) |
| TW (1) | TWI583383B (https=) |
| WO (1) | WO2011137734A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9102635B2 (en) * | 2013-02-14 | 2015-08-11 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| WO2017028814A1 (en) * | 2015-08-20 | 2017-02-23 | Tsh Biopharm Corporation Ltd. | Pharmaceutical composition comprising amlodipine and dextromethorphan |
| EP4620525A3 (en) | 2016-12-14 | 2025-12-03 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| KR20240096848A (ko) | 2017-01-25 | 2024-06-26 | 더 조지 인스티튜트 포 글로벌 헬스 | 고혈압의 치료를 위한 조성물 |
| US12521380B2 (en) | 2017-01-25 | 2026-01-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2676177A (en) | 1949-11-09 | 1954-04-20 | Hoffmann La Roche | Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof |
| GB8710493D0 (en) | 1987-05-02 | 1987-06-03 | Pfizer Ltd | Dihydropyridines |
| JPH06500554A (ja) * | 1990-08-23 | 1994-01-20 | ザ・チルドレンズ・メディカル・センター・コーポレイション | エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療 |
| JPH04368338A (ja) * | 1991-06-12 | 1992-12-21 | Taisho Pharmaceut Co Ltd | 鎮咳剤 |
| US5350756A (en) * | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| US6057344A (en) | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
| US5560913A (en) | 1995-01-27 | 1996-10-01 | The Procter & Gamble Company | Pharmaceutical compositions |
| EP1505068A4 (en) * | 2002-04-23 | 2008-03-19 | Shionogi & Co | PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE |
| US7923454B2 (en) * | 2002-05-17 | 2011-04-12 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| EP2987788A1 (en) * | 2002-05-17 | 2016-02-24 | Taiwanj Pharmaceuticals Co., Ltd. | Opioid and opioid-like compounds and uses thereof |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| KR100476636B1 (ko) | 2002-09-11 | 2005-03-17 | 한림제약(주) | 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법 |
| US7863287B2 (en) * | 2002-12-18 | 2011-01-04 | Wyeth Llc | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
| US8569374B2 (en) | 2004-09-16 | 2013-10-29 | The Trustees Of The University Of Pennsylvania | NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities |
| US20060188450A1 (en) * | 2005-02-24 | 2006-08-24 | Tim Clarot | System and method for suppressing a cough |
| US7939567B2 (en) * | 2006-02-24 | 2011-05-10 | Blue Blood Biotech Corp. | Dextromethorphan-based method for treating acne |
| US7820689B2 (en) * | 2006-08-10 | 2010-10-26 | Hua-Lin Wu | Methods and compositions for preventing or treating cardiovascular disease |
| US8569364B2 (en) * | 2007-11-28 | 2013-10-29 | Sequoia Pharmaceuticals, Inc. | 5-substituted benzofurans as inhibitors of cytochrome P450 2D6 |
-
2011
- 2011-04-29 WO PCT/CN2011/073560 patent/WO2011137734A1/en not_active Ceased
- 2011-04-29 MY MYPI2012004815A patent/MY161853A/en unknown
- 2011-04-29 EP EP11777155.0A patent/EP2566478A4/en not_active Withdrawn
- 2011-04-29 JP JP2013508361A patent/JP5847162B2/ja not_active Expired - Fee Related
- 2011-04-29 BR BR112012028153A patent/BR112012028153A2/pt not_active IP Right Cessation
- 2011-04-29 TW TW100115056A patent/TWI583383B/zh not_active IP Right Cessation
- 2011-04-29 US US13/695,628 patent/US20130053411A1/en not_active Abandoned
- 2011-04-29 AU AU2011250485A patent/AU2011250485B2/en not_active Ceased
- 2011-04-29 KR KR1020127031507A patent/KR20130061148A/ko not_active Ceased
- 2011-04-29 CN CN201180022318.4A patent/CN102869360B/zh not_active Expired - Fee Related
- 2011-04-29 RU RU2012151051/15A patent/RU2571284C2/ru not_active IP Right Cessation
-
2016
- 2016-04-28 US US15/141,381 patent/US9744165B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130061148A (ko) | 2013-06-10 |
| TW201206437A (en) | 2012-02-16 |
| US20130053411A1 (en) | 2013-02-28 |
| CN102869360B (zh) | 2015-03-25 |
| EP2566478A1 (en) | 2013-03-13 |
| JP5847162B2 (ja) | 2016-01-20 |
| US9744165B2 (en) | 2017-08-29 |
| AU2011250485B2 (en) | 2016-07-07 |
| AU2011250485A1 (en) | 2012-12-06 |
| EP2566478A4 (en) | 2014-04-30 |
| BR112012028153A2 (pt) | 2018-08-07 |
| CN102869360A (zh) | 2013-01-09 |
| WO2011137734A1 (en) | 2011-11-10 |
| TWI583383B (zh) | 2017-05-21 |
| RU2012151051A (ru) | 2014-06-10 |
| US20160235741A1 (en) | 2016-08-18 |
| JP2013525460A (ja) | 2013-06-20 |
| RU2571284C2 (ru) | 2015-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014500075A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| AU2008267058A8 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| EA200901339A1 (ru) | Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей | |
| MX2010006519A (es) | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. | |
| EA201270226A1 (ru) | Витамин d3 и его аналогии для лечения алопеции | |
| WO2011020061A3 (en) | Compositions and methods of for treating bipolar disorder | |
| IN2012DN02645A (https=) | ||
| PH12013502370A1 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| MY161853A (en) | Pharmaceutical composition and method for treating hypertension | |
| MY153948A (en) | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | |
| PH12013500411A1 (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| WO2008112773A3 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension | |
| MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| MX2010002667A (es) | Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3. | |
| EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| MX2010001116A (es) | Derivados novedosos de benzamidina, proceso para la preparacion de estos y composicion farmaceutica para la prevencion o el tratamiento de osteoporosis que comprende a los mismos. | |
| TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
| WO2009152052A8 (en) | Methods of treating alpha adrenergic mediated conditions | |
| WO2010042212A3 (en) | Methods for treating or preventing pain using spicamycin derivatives | |
| GB2459598A (en) | Heterodimers and methods of using them |